Partial liquid breathing of fluorocarbons
AssigneeAlliance Pharmaceutical Corp.
InventorsNicholas Simon Faithfull, Jeffry Greg Weers
Life of this patent
Estimating the term…
Abstract
The present invention includes a method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung, comprising the step of introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon liquid, the amount not exceeding the functional residual capacity of the lung of the patient upon exhalation taking into account any positive and expiratory pressure applied to the patient's lung. The method may also comprise the additional step of providing an oxygen-containing breathing gas to the patient while the fluorocarbon liquid is in the lung.
Claims26
A method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung, comprising the step of introducing into the lung of the patient an effective therapeutic amount of a fluorocarbon liquid, said amount being more than 0.1% and less than 50% of the functional residual capacity of the lung of the patient at the end of exhalation taking into account any positive and expiratory pressure applied to the patient's lung.
The method of claima 10, further comprising selecting the pharmaceutical agent from the group consisting of bronchodilators, expectorants, steroid, steroid derivatives, antibiotics, antivirals, anti-inflanmmatory agents, anti-allergics, antimitotic agents, anesthetics, analgesics and combinations thereof.
The method of claime 10 further comprising, providing a surfactant as the pharmaceutical agent.
A method for the pulmonary administration of a pharmaceutical agent to a patient comprising:
- administering to the pulmonary passages of the patient an effective therapeutic amount of a pharmaceutical agent dispersed in a fluorocarbon liquid wherein the volume of the fluorocarbon liquid administered is more than 0.1% and less than 50% of the functional residual capacity of the lung of the patient at the end of exhalation taking into account any positive or negative expiratory pressure applied to the patient's lung;
- and
- introducing a breathing gas into the patient's lung.
A method for treating a patient in need of facilitated oxygen delivery through the lungs, additional lung surfactant, removal of material from inside the lung, or inflation of collapsed portions of the lung, comprising the step of introducing into the lung of the patient an effective therapeutic amount of a perfluorooctylbromide liquid, said amount being more than 0.1% and less than 50% of the functional residual capacity of the lung of the patient at the end of exhalation taking into account any positive and expiratory pressure applied to the patient's lung.
Dependencies are inferred from the claim text.